PURPOSE: To demonstrate the feasibility of a novel macromolecular delivery system for doxorubicin (DOX) which combines pH dependent DOX release with a high molecular weight and biodegradable gelatin carrier. METHODS: DOX was conjugated to gelatin using an acid labile hydrazone bond and a glycylglycine linker. The gelatin-doxorubicin conjugate (G-DOX) was evaluated for hydrazide and DOX content by spectrophotometry, molecular weight by HPLC-SEC, in vitro DOX release at various pH, and cell growth inhibition using EL4 mouse lymphoma and PC3 human prostate cells. RESULTS: G-DOX hydrazide and DOX content was 47% and 5-7%, respectively of theoretical gelatin carboxylic acid sites. During preparation of G-DOX, the molecular weight decreased to 22 kDa. DOX release was 48% in pH 4.8 phosphate buffer, 22% at pH 6.5, but 10% at pH 7.4. The G-DOX IC50 values in EL4 and PC3 cells were 0.26 μM and 0.77 μM, respectively; the latter value 3 times greater than that of free DOX. CONCLUSIONS: A 22 kDa macromolecular DOX conjugate containing 3.4-5.0% w/w DOX has been prepared. The pH dependent drug release in combination with a biodegradable gelatin carrier offer potential therapeutic advantages of enhanced tumor cell localization and reduced systemic toxicities of the drug.
PURPOSE: To demonstrate the feasibility of a novel macromolecular delivery system for doxorubicin (DOX) which combines pH dependent DOX release with a high molecular weight and biodegradable gelatin carrier. METHODS:DOX was conjugated to gelatin using an acid labile hydrazone bond and a glycylglycine linker. The gelatin-doxorubicin conjugate (G-DOX) was evaluated for hydrazide and DOX content by spectrophotometry, molecular weight by HPLC-SEC, in vitro DOX release at various pH, and cell growth inhibition using EL4mouselymphoma and PC3human prostate cells. RESULTS:G-DOX hydrazide and DOX content was 47% and 5-7%, respectively of theoretical gelatin carboxylic acid sites. During preparation of G-DOX, the molecular weight decreased to 22 kDa. DOX release was 48% in pH 4.8 phosphate buffer, 22% at pH 6.5, but 10% at pH 7.4. The G-DOX IC50 values in EL4 and PC3 cells were 0.26 μM and 0.77 μM, respectively; the latter value 3 times greater than that of free DOX. CONCLUSIONS: A 22 kDa macromolecular DOX conjugate containing 3.4-5.0% w/w DOX has been prepared. The pH dependent drug release in combination with a biodegradable gelatin carrier offer potential therapeutic advantages of enhanced tumor cell localization and reduced systemic toxicities of the drug.
Authors: K Kataoka; T Matsumoto; M Yokoyama; T Okano; Y Sakurai; S Fukushima; K Okamoto; G S Kwon Journal: J Control Release Date: 2000-02-14 Impact factor: 9.776
Authors: Tomáš Etrych; Lubomír Kovář; Jiří Strohalm; Petr Chytil; Blanka Ríhová; Karel Ulbrich Journal: J Control Release Date: 2011-06-15 Impact factor: 9.776
Authors: Tomáš Etrych; Vladimír Subr; Jiří Strohalm; Milada Sírová; Blanka Ríhová; Karel Ulbrich Journal: J Control Release Date: 2012-06-30 Impact factor: 9.776
Authors: Kamal K Upadhyay; Anant N Bhatt; Anil K Mishra; Bilikere S Dwarakanath; Sanyog Jain; Christophe Schatz; Jean-François Le Meins; Abdullah Farooque; Godugu Chandraiah; Amit K Jain; Ambikanandan Misra; Sébastien Lecommandoux Journal: Biomaterials Date: 2010-01-06 Impact factor: 12.479
Authors: Xinghe Wang; Gang Zhao; Sang Van; Nan Jiang; Lei Yu; David Vera; Stephen B Howell Journal: Cancer Chemother Pharmacol Date: 2009-07-11 Impact factor: 3.333
Authors: P A Vasey; S B Kaye; R Morrison; C Twelves; P Wilson; R Duncan; A H Thomson; L S Murray; T E Hilditch; T Murray; S Burtles; D Fraier; E Frigerio; J Cassidy Journal: Clin Cancer Res Date: 1999-01 Impact factor: 12.531